Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Significant Growth in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 538,588 shares, an increase of 1,973.5% from the February 12th total of 25,975 shares. Based on an average daily volume of 1,546,018 shares, the days-to-cover ratio is presently 0.3 days. Currently, 55.6% of the company’s shares are sold short. Currently, 55.6% of the company’s shares are sold short. Based on an average daily volume of 1,546,018 shares, the days-to-cover ratio is presently 0.3 days.

Sensei Biotherapeutics Price Performance

SNSE stock traded up $0.50 on Tuesday, hitting $30.00. 86,366 shares of the company were exchanged, compared to its average volume of 777,995. Sensei Biotherapeutics has a twelve month low of $5.00 and a twelve month high of $36.76. The business’s fifty day moving average is $16.21 and its two-hundred day moving average is $11.76. The stock has a market capitalization of $37.80 million, a price-to-earnings ratio of -1.57 and a beta of -0.12.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SNSE has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded Sensei Biotherapeutics to a “hold” rating in a research report on Saturday, December 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.